Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 5/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | TP53 | P04637 | 2/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2192211 | 0.95 | TSHR (0.45) | MEN1KMT2ATSHRMAPK1TDP1 | |
| SCHEMBL27978106 | 0.92 | TSHR (0.43) | MEN1KMT2ATSHRMAPK1TDP1 | |
| SCHEMBL28250371 | 0.92 | TSHR (0.43) | MEN1KMT2ATSHRMAPK1TDP1 | |
| SCHEMBL12565652 | 0.92 | TSHR (0.42) | MEN1KMT2ATSHRMAPK1TDP1 | |
| SCHEMBL4528968 | 0.90 | MEN1 (0.52) | MEN1KMT2ATSHRMAPK1TDP1 | |
| SCHEMBL14521446 | 0.90 | TSHR (0.45) | MEN1KMT2ATSHRMAPK1TDP1 | |
| SCHEMBL3265777 | 0.89 | TDP1 (0.36) | MEN1KMT2ATSHRMAPK1TDP1 | |
| SCHEMBL14428578 | 0.87 | MEN1 (0.39) | MEN1KMT2ATSHRMAPK1TDP1 | |
| SCHEMBL4139271 | 0.87 | ALDH1A1 (0.52) | MEN1KMT2ATSHRTDP1MGLL | |
| SCHEMBL14134498 | 0.84 | MEN1 (0.40) | MEN1KMT2ATSHRMAPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962784-B2 | Isocyanate terminated macromer and formulation thereof for use as an internal adhesive or sealant | ETHICON, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20100158849-A1 | ISOCYANATE TERMINATED MACROMER AND FORMULATION THEREOF FOR USE AS AN INTERNAL ADHESIVE OR SEALANT | ETHICON, INC. | 2010-06-24 | — | — | US | disclosed |
| EP-1223951-A4 | METHOD OF PREVENTING ADHESIONS WITH ABSORBABLE POLYOXAESTERS | ETHICON INC (US) | 2003-05-02 | — | — | EP | disclosed |
| EP-1223951-A1 | METHOD OF PREVENTING ADHESIONS WITH ABSORBABLE POLYOXAESTERS | ETHICON, INC. (US) | 2002-07-24 | — | — | EP | disclosed |
| WO-2001012203-A1 | METHOD OF PREVENTING ADHESIONS WITH ABSORBABLE POLYOXAESTERS | ETHICON, INC. (US) | 2001-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100158849-A1 | ISOCYANATE TERMINATED MACROMER AND FORMULATION THEREOF FOR USE AS AN INTERNAL ADHESIVE OR SEALANT | ICAM1, ILK, MACF1 | MEN1 889/4885KMT2A 692/4885TSHR 4859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.